December 8, 2010 New Cialis (tadalafil) Overtakes Viagra to Become Number One Selling Erectile Dysfunction Treatment in France
Erectile Dysfunction Drug
Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS) reported� � on April 18� � that Cialis� � (tadalafil)(1), the only erectile dysfunction (ED) treatment clinically proven to work up to 36 hours for most men, has surpassed Viagra� � (sildenafil citrate) in France for the second consecutive month.
In January 2005, Cialis accounted for 45 percent of the total PDE5 inhibitor tablets sold from wholesalers to pharmacies in France; Viagra’s total for that same period was 44 percent. For the month of February 2005, Cialis continued its growth in France by attaining 49 percent of tablets sold from wholesalers to pharmacies, while Viagra had the second largest share with 40 percent, according to the latest IMS market share information.(2)
The market share of Cialis in France has grown consistently since the product was introduced in Europe in February 2003. Since December 2004, Cialis has secured an additional 6.4 percentage points of the total share of tablets from wholesalers to pharmacies to gain the largest share of sales in the French market.
“The success of Cialis in France is an exciting milestone for the brand and for Lilly ICOS, especially because we joined the market after the leader was so well established,” said Leonard Blum, ICOS Vice President, Sales and Marketing. “The key benefit of Cialis, the up-to-36 hours that Cialis gives a man and his partner to choose the moment for intimacy that’s right for them, is the reason we have always said Cialis would succeed in the Erectile Dysfunction marketplace. This benefit means couples who don’t want to schedule romance can have time to relax and, for instance, have dinner or simply enjoy time together, allowing intimacy to happen when the moment is right.”
Since its approval in the United States in November 2003, Cialis has increased its share of total prescriptions every month in the U.S. For the week ended April 1, 2005, Cialis held a 24 percent share of new and 22 percent of total U.S. oral Erectile Dysfunction� � treatment prescriptions.(3)
“We are not surprised by the success of Cialis in France, a country many people associate with romance and love,” said Matt Beebe, Cialis U.S. Brand Team Leader, Lilly. “Here in the U.S., where Cialis was the third product to enter a very competitive market, we have our own success story – just four months after launch, Cialis secured the second largest share of the ED market. We’re pleased to see the market share of Cialis continue to grow each month as more and more men discover the benefits Cialis has to offer.”
December 3, 2010 Prevalence of Erectile Dysfunction and Use of ED Medications Among Teens, Young Men
Erectile dysfunction medications and youth
A new study indicates a high prevalence of erectile dysfunction (ED) and evidence of recreational use of erectile dysfunction medications (EDM) among adolescents and young men.
Researchers at Children’s Memorial Hospital and Northwestern University’s Feinberg School of Medicine conducted an anonymous survey of 234 sexually active males between the ages of 18-25 on the campuses of three national universities in Chicago. This survey � � � � � � � �” the first of its kind � � � � � � � �” found that a significant number of surveyed young men had used erectile dysfunction medications (EDM) such as Viagra� � � � � � � � � – many in conjunction with other recreational drugs, and most without consulting their physician.
Often associated with sexual dissatisfaction, decreased quality of life, depression and anxiety,� � erectile dysfunction has rarely been studied in adolescent males. This first study to gauge ED occurring with condom use (EDwC) indicates that men who have experienced ED while putting on a condom are four times more likely to use condoms inconsistently.
13%� � of the respondents reported erectile dysfunction, defined as “ever had difficulty getting or keeping an erection,” but rarely discussed this with their medical providers.� � 25% reported� � erectile dysfunction occurring with condom use. “Our exploratory study examines the prevalence and correlates of ED, EDwC and EDM use in a community-based sample of college-age males,” said Najah Musacchio, MD, fellow in General Academic Pediatrics and lead investigator. “Participants with EDwC were 4 times more likely to use condoms inconsistently, and 5 times more likely to have multiple sex partners in the last year, suggesting that EDwC may represent a barrier to safer sex and play a role in STI transmission,” said Robert Garofalo, Director of Adolescent HIV Services.
A total of 302 college-age males completed a self-administered survey. Oral consent was obtained before survey administration. Sixty-eight participants (23%) reported no anal/vaginal sex in the past year and were excluded from analysis. Participants were predominantly white (66%), ages 18-20 (64%) and heterosexual (95%). Most (83%) had one to five sexual partners in the past year and 47% reported 100% condom use for anal/vaginal sex. Six participants (3%) had a prior STI, five of whom were men who have sex with men (MSM).
6%� � of surveyed men used erectile dysfunction medications.� � 57% of participants who took EDM used them to treat erectile dysfunction; 29% used them to enhance sexual performance.� � 64% percent of� � erectile dysfunction medications users mixed EDM with alcohol or illicit drugs; 36% with multiple other drugs. “Particularly concerning is mixing Viagra� � � � � � � and other EDM with alcohol and drugs, such as ecstasy or methamphetamine,” said Musacchio. “Such drugs boost sex drive and reduce inhibitions, yet impair sexual performance.� � erectile dysfunction medication use may permit men in altered mental and physical states to engage in unsafe sexual behaviors, creating concern for unwanted pregnancy and sexually transmitted infections (STI).”
Survey participants rarely obtained their� � erectile dysfunction medication from a medical provider: most (54%) got EDM from their friends or other non-medical sources (39%) such as the Internet.
In studies with adult men who have sex with men (MSM), Viagra� � � � � � � use has similarly been associated with risky sex (increased number of sex partners, higher rates of STIs, and unprotected sex with HIV-positive partners). “Although small in number, the young MSM in our sample reported disproportionate� � erectile dysfunction medication use and STIs, possibly warranting exploration of these issues in this adolescent subpopulation,” said Musacchio.
Survey findings suggest that� � erectile dysfunction and EDwC occur with some frequency in adolescents, and that these issues are rarely discussed with medical providers. Given the association between ED and negative health outcomes such as depression and sexual dissatisfaction, medical providers should ask adolescent males about ED and counsel them on potential health risks of� � erectile dysfunction medication and substance use, they advised. Providers should specifically inquire about EDwC, stressing the importance of using condoms with all sexual encounters.
“The topic must be addressed,” Musacchio said. “Data indicates that ED and� � erectile dysfunction medications use is not uncommon in young males. It should be openly discussed in the medical community and between provider and patient � � � � � � � �” especially since it can lead to unsafe sex and other health risks.”
Erectile Dysfunction Drug Uprima
Two-thirds of patients stopped using Uprima, a drug commonly prescribed for erection problems, because they felt it wasn’t effective, according to a large-scale study published in the July issue of the urology journal BJU International.
And 70 per cent of family doctors who expressed an opinion using an official National Health Service (NHS) drug feedback form felt the drug wasn’t effective.
Researchers at the UK’s Drug Safety Research Unit and University of Portsmouth analysed prescribing data for 11,185 patients seen by NHS family doctors.
The data was gathered from official Green Form Questionnaires that ask doctors to record any significant events recorded in a patient’s notes after prescribing newly marketed medicines.
Key findings on erectile dysfunction drug:
- 65 per cent of doctors said their patient stopped taking Uprima because they felt it wasn’t effective and 14 per cent said the patient didn’t request a further prescription. (68 per cent of GPs responded to the question).
- Further analysis showed that 59 per cent of patients who didn’t find it effective stopped taking Uprima after a month and a further 23 had joined them by month two. (Timescale information was recorded for 79 per cent of patients who judged the drug ineffective).
- 70 per cent of doctors said they didn’t think the drug was effective and 30 per cent said it was. (65 per cent of GPs responded to the question)
- 28.5 per cent of the total patient sample had a history of diabetes, 18.8 per cent had heart disease and 37.2 per cent had tried Viagra. 7.5 per cent were receiving both Uprima and nitrate therapy for angina.
- The most common adverse drug reactions were headache and nausea, in line with the clinical trials and as listed in the Summary of Product Characteristics by the manufacturers.
- The average age of the subjects was 61 and all but eight were male. Three of the women were prescribed Uprima for decreased libido, pain and sexual arousal problems. Prescribing information was not provided for the other five.
- Most patients (99 per cent) received the manufacturer’s recommended dose of 2-3mg, with the remainder receiving between 4-12mg. (Starting dose information was completed on 79 per cent of forms).
- 99 deaths (just under one per cent of the total sample) were recorded on the forms. The most frequently reported cause of death was heart attack (27 patients), followed by heart disease (nine) and lung cancer (five). In 21 cases the cause of death could not be established by the researchers.
The 11,185 forms covered patients who were first prescribed Uprima between October 2001 – three months after the drug was launched in the UK – and December 2002. Just over 21,000 Questionnaires were issued and 57 per cent of GPs responded.
At least six months after the first prescription for Uprima was issued for each patient, their family doctor was sent a Green Form Questionnaire that requested details about the patient’s age and sex and their use of Uprima.
They were also asked to record any significant events that had occurred since the patient was prescribed Uprima, such as suspected drug reactions, unexpected deterioration or improvement in the patient’s condition, referral to a specialist or any clinically important changes in laboratory tests.
The form also included questions on diseases commonly associated with erectile dysfunction – such as diabetes and heart disease � � � � � � � �” together with previous use of similar drugs and co-prescribing of medication for angina.
“Prescription-Event Monitoring provides surveillance on a national scale after new drugs are launched” explains lead researcher Professor Saad Shakir.
“Because family doctors are not approached before the decision to treat a patient has been made, they are not subject to detailed inclusion or exclusion criteria. The decision to prescribe is made purely as a result of their clinical knowledge of the patient and the drug involved.
“The result is real world clinical data that provides information of illness and death in patients treated with newly marketed drugs � � � � � � � �” a valuable tool in drug safety assessment.”
Hong Kong Department Of Health appealed to members of the public not to buy or use a product named “Chong Cao Ju Wang” as it was found to contain an undeclared drug which is known to link with serious side effects.
A DH spokesman said a 69-year-old man was admitted to United Christian Hospital on July 23 after he was found unconscious at home. His blood glucose level was very low on admission.
Investigation revealed that he had a history of taking the above mentioned product purchased at a drug shop in Shenzhen. The urine of the patient was found to have contained glibenclamide (a diabetic drug) and sildenafil (a drug used for treating male sexual dysfunction).
Today, laboratory tests on one remaining capsule of the product provided by the patient showed the presence of sildenafil.
The spokesman said glibenclamide could cause nausea and gastro-intestinal upset. Improper use may cause a significant fall in blood sugar level with serious health consequence and even death.
The side effects of sildenafil include low blood pressure, headache, vomiting, dizziness, and transient vision disturbances. It may interact with nitrates found in some prescription drugs (such as nitroglycerin for treatment of angina) and may lower blood pressure of patients to dangerous levels. Improper use of sildenafil may pose serious health risks, especially for patients with heart problems.
Under the Pharmacy and Poisons Ordinance of Hong Kong, products containing either sildenafil or glibenclamide must be registered before sale and can only be sold on a doctor’s prescription and under supervision of a pharmacist.
Members of the public who have bought the product are advised not to take it. Moreover, they are urged to seek advice from their doctors if feeling unwell after consuming the product.
They should destroy and dispose of the products or submit them to the Department’s Pharmaceutical Service at 3/F, Public Health Laboratory Centre, 382 Nam Cheong Street, Kowloon, during office hours.
“People who have problems of sexual dysfunction should consult medical professionals for appropriate advice or medication,” the spokesman said.
Erectile dysfunction, sometimes called Impotence, is the repeated inability to get or keep an erection firm enough for sexual intercourse. The word “impotence” may also be used to describe other problems that interfere with sexual intercourse and reproduction, such as lack of sexual desire and problems with ejaculation or orgasm. Using the term erectile dysfunction makes it clear that those other problems are not involved.
Erectile dysfunction, or ED, can be a total inability to achieve erection, an inconsistent ability to do so, or a tendency to sustain only brief erections. These variations make defining erectile dysfunction and estimating its incidence difficult. Estimates range from 15 million to 30 million, depending on the definition used. According to the National Ambulatory Medical Care Survey (NAMCS), for every 1,000 men in the United States, 7.7 physician office visits were made for Erectile Dysfunction in 1985. By 1999, that rate had nearly tripled to 22.3. The increase happened gradually, presumably as treatments such as vacuum devices and injectable drugs became more widely available and discussing erectile function became accepted. Perhaps the most publicized advance was the introduction of the oral drug sildenafil citrate (Viagra) in March 1998. NAMCS data on new drugs show an estimated 2.6 million mentions of Viagra at physician office visits in 1999, and one-third of those mentions occurred during visits for a diagnosis other than Erectile Dysfunction or Impotence.
In older men, Erectile Dysfunction usually has a physical cause, such as disease, injury, or side effects of drugs. Any disorder that causes injury to the nerves or impairs blood flow in the penis has the potential to cause Erectile Dysfunction. Incidence increases with age: About 5 percent of 40-year-old men and between 15 and 25 percent of 65-year-old men experience Erectile Dysfunction (Impotence). But it is not an inevitable part of aging.
Erectile Dysfunction is treatable at any age, and awareness of this fact has been growing. More men have been seeking help and returning to normal sexual activity because of improved, successful treatments for Erectile Dysfunction. Urologists, who specialize in problems of the urinary tract, have traditionally treated Erectile Dysfunction; however, urologists accounted for only 25 percent of Viagra mentions in 1999.
How does an erection occur?
The penis contains two chambers called the corpora cavernosa, which run the length of the organ. A spongy tissue fills the chambers. The corpora cavernosa are surrounded by a membrane, called the tunica albuginea. The spongy tissue contains smooth muscles, fibrous tissues, spaces, veins, and arteries. The urethra, which is the channel for urine and ejaculate, runs along the underside of the corpora cavernosa and is surrounded by the corpus spongiosum.
Erection begins with sensory or mental stimulation, or both. Impulses from the brain and local nerves cause the muscles of the corpora cavernosa to relax, allowing blood to flow in and fill the spaces. The blood creates pressure in the corpora cavernosa, making the penis expand. The tunica albuginea helps trap the blood in the corpora cavernosa, thereby sustaining erection. When muscles in the penis contract to stop the inflow of blood and open outflow channels, erection is reversed.